Cotinine replacement levels for a 21 mg/day transdermal nicotine patch in an outpatient treatment setting.
This study examined plasma cotinine replacement levels of 56 outpatient smokers administered a 21 mg/day transdermal nicotine patch (Nicoderm CQ ). The percentage of cotinine replacement ranged from 35 to 232% (mean 107%; median 90.5%). Four subject variables were found to be significantly correlated with percentage of cotinine replacement-baseline cotinine level, prior quit attempts, gender, and the Fagerström Tolerance Questionnaire score. A two-variable model consisting of baseline cotinine level and gender provided the most powerful predictor combination. The percentage of cotinine replacement was not predictive of post-treatment smoking. The relatively high levels of cotinine replacement obtained using the Nicoderm CQ 21 mg/day patch suggest cautious use of higher dose treatment with this particular patch.
Gariti
P
P
University of Pennsylvania, School of Medicine, Philadelphia 19104, USA.
Alterman
A I
AI
Barber
W
W
Bedi
N
N
Luck
G
G
Cnaan
A
A
D000279:Administration, Cutaneous; D000328:Adult; D015415:Biomarkers / Q000097:blood; D016009:Chi-Square Distribution; D018678:Cholinergic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D003367:Cotinine / Q000097:blood*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D012737:Sex Factors; D016540:Smoking Cessation / Q000379:methods; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control; D014029:Tobacco Use Disorder / Q000097:blood* / Q000188:drug therapy; D016896:Treatment Outcome
D015415:Biomarkers; D018678:Cholinergic Agents; D009538:Nicotine; D003367:Cotinine